Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-100
SponsorOur Lady of the Lake Hospital
About this trial
EGFR gene mutations are some of the most commonly occurring mutations in non-small cell lung cancer. Investigators have developed a DNA instability model that estimates a risk score to assess the likelihood of an individual acquiring a cancer-linked mutation. The aim of this study is to collect blood from both those diagnosed with EGFR positive lung cancer and healthy individuals, evaluate their gene sequence surrounding the EGFR landscape and use the cancer positive and healthy sequences to validate the risk assessment model, which may one day be used to provide insight on susceptibility of getting EGFR positive lung cancer or potentially other cancer types.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18-100 years old
Biologically born female
Diagnosed with EGFR positive lung cancer (Arm 1-Cancer group)
No cancer diagnosis (Arm 2-health control)
Disqualifiers
less than 18 years of age
Biologically born male
Incarcerated at the time of participation
Trial population
Female adult subjects who have EGFR positive lung cancer
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
blood draw
Other interventionA 10ml Blood sample will be taken and used to sequence the EGFR gene and surrounding DNA.
Gene sequencing
Other interventionSubjects will have their DNA sequenced within and around the EGFR gene.
Treatment groups
20 Participants
are divided into 2 treatment groupsGroup A: EGFR Positive Lung Cancer2 interventions
Group B: Healthy Subjects2 interventions
Trial outcomes
Primary outcomes
1
Differences in DNA sequence of EGFR gene
Subjects who have EGFR positive lung cancer will have their gene sequence compared to those that are EGFR negative and do not have lung cancer to look for differences in the sequence.
Time frame
From enrollment to end of data analysis at 6 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov